Janus Henderson Group plc Increases Stake in Bright Minds Biosciences Inc. to 13.1%

On May 15, 2026, Janus Henderson Group plc filed a Schedule 13G/A reporting a significant increase in its position in Bright Minds Biosciences Inc. (DRUG). The filer now beneficially owns 1,284,324 shares of common stock, representing a 13.1% ownership stake in the company. This is a substantial increase from a previous 0.0% position reported in prior filings. Janus Henderson Group plc serves as the parent holding company for various SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over the shares on behalf of managed portfolios. Specifically, the Janus Henderson Biotech Innovation Master Fund Ltd. was identified as having the right to receive dividends or proceeds from more than 5% of the common stock. The filing indicates that these shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.